IJOC  Vol.2 No.3 , September 2012
Reductive Amination with [11C]Formaldehyde: A Versatile Approach to Radiomethylation of Amines
Abstract: Carbon-11 radiolabeled amines constitute a very important class of radioligands that are widely used for positron emission tomography (PET) imaging. Radiolabeling of amines is often achieved through radiomethylation using [11C]CH3I or [11C]CH3OTf under basic conditions in a strictly anhydrous environment. Functional groups such as hydroxyl and carboxyl groups that are often present in the molecules are normally base sensitive and require protection and deprotection, which substantially prolongs and complicates the radiolabeling process. Here we report a versatile approach to a series of C-11 radiolabeled amines prepared through reductive amination using [11C]formaldehyde. Using a variety of substrates bearing different functional groups, we demonstrate the general utility of this method. In contrast to conventional radiomethylation methods, the reductive amination using [11C]formaldehyde can be carried out in an aqueous environment relatively quickly without the need of protection of base-sensitive functional groups.
Cite this paper: C. Wu, R. Li, D. Dearborn and Y. Wang, "Reductive Amination with [11C]Formaldehyde: A Versatile Approach to Radiomethylation of Amines," International Journal of Organic Chemistry, Vol. 2 No. 3, 2012, pp. 202-223. doi: 10.4236/ijoc.2012.23030.

[1]   C. A. Mathis, Y. Wang, D. P. Holt, G. F. Huang, M. L. Debnath and W. E. Klunk, “Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents,” Journal of Medicinal Chemistry, Vol. 46, No. 13, 2003, pp. 2740-2754. doi:10.1021/jm030026b

[2]   C. Solbach, M. Uebele, G. Reischl and H. J. Machulla, “Efficient Radiosynthesis of Carbon-11 Labelled Uncharged Thioflavin T Derivatives Using [11C]Methyl Triflate for Beta-Amyloid Imaging in Alzheimer’s Disease With Pet,” Applied Radiation and Isotopes, Vol. 62, No. 4, 2005, pp. 591-595. doi:10.1016/j.apradiso.2004.09.003

[3]   N. M. Kemppainen, S. Aalto, I. A. Wilson, K. Nagren, S. Helin, A. Bruck, V. Oikonen, M. Kailajarvi, M. Scheinin, M. Viitanen, R. Parkkola and J. O. Rinne, “PET Amyloid Ligand [11C]PIB Uptake Is Increased in Mild Cognitive Impairment,” Neurology, Vol. 68, No. 19, 2007, pp. 1603- 1606. doi:10.1212/01.wnl.0000260969.94695.56

[4]   S. Houle, N. Ginovart, D. Hussey, J. H. Meyer and A. A. Wilson, “Imaging the Serotonin Transporter with Positron Emission Tomography: Initial Human Studies with [11C]- DAPP and [11C]DASB,” European Journal of Nuclear Medicine and Molecular Imaging, Vol. 27, No. 11, 2000, pp. 1719-1722. doi:10.1007/s002590000365

[5]   S. J. Kish, J. Lerch, Y. Fu-rukawa, J. Tong, T. McCluskey, D. Wilkins, S. Houle, J. Meyer, E. Mundo, A. A. Wilson, P. M. Rusjan, J. A. Saint-Cyr, M. Guttman, D. L. Collins, C. Shapiro, J. J. Warsh and I. Boileau, “Decreased Cerebral Cortical Serotonin Transporter Binding in Ecstasy Users: A Positron Emission Tomography/[(11)C]DASB and Structural Brain Imaging Study,” Brain, Vol. 133, No. 6, 2010, pp. 1779-1797. doi:10.1093/brain/awq103

[6]   K. Yanamoto, T. Yamasaki, K. Kumata, J. Yui, C. Odawara, K. Kawamura, A. Hatori, O. Inoue, M. Yamaguchi, K. Suzuki and M. R. Zhang, “Evaluation of N- ben-zyl-N-[11C]methyl-2-(7-methyl-8-oxo-2-phenyl-7,8- dihydro-9H-purin-9-yl)acetamide ([11C]DAC) as a Novel Translocator Protein (18 kDa) Radioligand in Kainic Acid-Lesioned Rat,” Synapse, Vol. 63, No. 11, 2009, pp. 961-971. doi:10.1002/syn.20678

[7]   G. Hagberg, O. Gefvert, M. Berg-strom, I. M. Wieselgren, L. Lindstrom, F. A. Wiesel and B. Langstrom, “N-[11C]- methylspiperone PET, in Contrast to [11C]Raclopride, Fails to Detect D2 Receptor Occupancy by an Atypical Neuroleptic,” Psychiatry Research: Neuroimaging, Vol. 82, No. 3, 1998, pp. 147-160. doi:10.1016/S0925-4927(98)00020-1

[8]   P. Rosa-Neto, A. Gjedde, A. K. Olsen, S. B. Jensen, O. L. Munk, H. Watanabe and P. Cumming, “MDMA-Evoked Changes in [11C]Raclopride and [11C]NMSP Binding in Living Pig Brain,” Synapse, Vol. 53, No. 4, 2004, pp. 222-233. doi:10.1002/syn.20053

[9]   M. E. Pierson, J. Andersson, S. Nyberg, D. J. McCarthy, S. J. Finnema, K. Varnas, A. Takano, P. Karlsson, B. Gulyas, A. M. Medd, C. M. Lee, M. E. Powell, J. R. Heys, W. Potts, N. Seneca, L. Mrzljak, L. Farde and C. Halldin, “[11C]AZ10419369: A Selective 5-HT1B Receptor Radioligand Suitable for Positron Emission Tomography (PET). Characterization in the Primate Brain,” Neuroimage, Vol. 41, No. 3, 2008, pp. 1075-1085. doi:10.1016/j.neuroimage.2008.02.063

[10]   C. Halldin, S. Stone-Elander, L. Farde, E. Ehrin, K. J. Fasth, B. Langstrom and G. Sedvall, “Preparation of 11C-Labelled SCH 23390 for the in Vivo Study of Dopa- mine D-1 Receptors Using Positron Emission Tomography,” International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Iso- topes, Vol. 37, No. 10, 1986, pp. 1039-1043. doi:10.1016/0883-2889(86)90044-4

[11]   A. A. Wilson, P. McCormick, S. Kapur, M. Willeit, A. Garcia, D. Hussey, S. Houle, P. Seeman and N. Ginovart, “Radiosynthesis and Eval-uation of [11C]-(+)-4-Propyl- 3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a Potential Radiotracer for in Vivo Imaging of the Dopamine D2 High-Affinity State with Positron Emission Tomography,” Journal of Medicinal Chemistry, Vol. 48, No. 12, 2005, pp. 4153-4160. doi:10.1021/jm050155n

[12]   V. L. Cropley, M. Fujita, J. L. Musachio, J. Hong, S. Ghose, J. Sangare, P. J. Na-than, V. W. Pike and R. B. Innis, “Whole-Body Biodistribution and Estimation of Radiation-Absorbed Doses of the Dopamine D1 Receptor Radioligand 11C-NNC 112 in Humans,” Journal of Nuclear Medicine, Vol. 47, 2006, pp. 100-104.

[13]   K. Marthi, D. Bender, A. Gjedde and D. F. Smith, “[11C]- Mirtazapine for PET Neuroimaging: Radiosynthesis and Initial Evaluation in the Living Porcine Brain,” European Neuropsychopharmacology, Vol. 12, No. 5, 2002, pp. 427- 432. doi:10.1016/S0924-977X(02)00049-4

[14]   K. Marthi, S. Jakobsen, D. Bender, S. B. Hansen, S. B. Smith, F. Hermansen, R. Rosenberg and D. F. Smith, “[N-Methyl-11C]mirtazapine for Positron Emission Tomography Neuroimaging of Antide-pressant Actions in Humans,” Psychopharmacology, Vol. 174, No. 2, 2004, pp. 260-265. doi:10.1007/s00213-003-1754-x

[15]   K. Ishiwata, T. Nariai, Y. Kimura, K. Oda, K. Kawamura, K. Ishii, M. Senda, S. Waka-bayashi and J. Shimada, “Preclinical Studies on [11C]MPDX for Mapping Adenosine A1 Receptors by Positron Emission To-mography,” Annals of Nuclear Medicine, Vol. 16, No. 6, 2002, pp. 377-382. doi:10.1007/BF02990074

[16]   P. H. Elsinga, E. J. Franssen, N. H. Hendrikse, L. Fluks, A. M. Weemaes, W. T. van der Graaf, E. G. de Vries, G. M. Visser and W. Vaalburg, “Carbon-11-Labeled Daun- orubicin and Verapamil for Probing P-Glycoprotein in Tumors with PET,” Journal of Nuclear Medicine, Vol. 37, No. 9, 1996, pp. 1571-1575.

[17]   K. Hashimoto, O. Inoue, K. Suzuki, T. Yamasaki and M. Kojima, “Synthesis and Evaluation of 11C-PK 11195 for in Vivo Study of Peripheral-Type Benzodiazepine Receptors Using Positron Emission Tomography,” Annals of Nuclear Medicine, Vol. 3, No. 2, 1989, pp. 63-71. doi:10.1007/BF03164587

[18]   D. M. Raffel, J. R. Corbett, R. B. del Rosario, S. K. Mukhopadhyay, D. L. Gildersleeve, P. Rose and D. M. Wieland, “Sensitivity of [11C]Phenylephrine Kinetics to Mo- noamine Oxidase Activity in Normal Human Heart,” Journal of Nuclear Medicine, Vol. 40, No. 2, 1999, pp. 232- 238.

[19]   M. Verdurand, G. Bort, V. Tadino, F. Bonnefoi, D. Le Bars and L. Zimmer, “Automated Radiosynthesis of the Pittsburg Compound-B Using a Commercial Synthesizer,” Nuclear Medicine Communications, Vol. 29, No. 10, 2008, pp. 920-926. doi:10.1097/MNM.0b013e328304e0e1

[20]   M. van der Meij, N. I. Carruthers, J. D. M. Herscheid, J. A. Jablonowski, J. E. Leysen and A. D. Windhorst, “Re- ductive N-Alkylation of Secondary Amines with [2-11C]- Acetone,” Journal of Labelled Compounds and Radio- pharmaceuticals, Vol. 46, No. 11, 2003, pp. 1075-1085.

[21]   O. Rahman, T. Kihlberg and B. L?ngstr?m “Synthesis of 11C-/13C-Ketones by Suzuki Coupling,” European Journal of Organic Chemistry, Vol. 2004, No. 3, 2004, pp. 474-478. doi:10.1002/ejoc.200300527

[22]   J. M. Hooker, M. Schonberger, H. Schieferstein and J. S. Fowler, “A Simple, Rapid Method for the Preparation of [11C]Formaldehyde,” Angewandte Chemie International Edition, Vol. 47, No. 32, 2008, pp. 5989-5992.

[23]   A. Sun, J. Sorensen, M. Karlsson, I. Turesson, B. Langstrom, P. Nilsson, L. Cederblad, J. Bertling, K. Riklund and S. Johansson, “1-[11C]-Acetate PET Imaging in Head and Neck Cancer—A Comparison with 18F-FDG-PET: Implications for Staging and Radiotherapy Planning,” European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, No. 5, 2007, pp. 651-657. doi:10.1007/s00259-006-0298-9

[24]   I. Boileau, S. Houle, P. M. Rusjan, Y. Furukawa, D. Wilkins, J. Tong, P. Selby, A. A. Wilson and S. J. Kish, “Influence of a Low Dose of Am-phetamine on Vesicular Monoamine Transporter Binding: A PET (+)[11C]DTBZ Study in Humans,” Synapse, Vol. 64, No. 6, 2010, pp. 417-420. doi:10.1002/syn.20743

[25]   A. F. Ab-del-Magid, K. G. Carson, B. D. Harris, C. A. Maryanoff and R. D. Shah, “Reductive Amination of Al-dehydes and Ketones with Sodium Triacetoxyboro-hydride. Studies on Direct and Indirect Reductive Amination Procedures(1),” Journal of Organic Chemistry, Vol. 61, No. 11, 1996, pp. 3849-3862. doi:10.1021/jo960057x

[26]   C. Wu, C. Wang, D. C. Popescu, W. Zhu, E. A. Somoza, J. Zhu, A. G. Condie, C. A. Flask, R. H. Miller, W. Macklin and Y. Wang, “A Novel PET Marker for in Vivo Quantification of Myelination,” Bioorganic & Medicinal Chemistry, Vol. 18, No. 24, 2010, pp. 8592-8599.